Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Heptares Pharma

Teva Pharma logo

Cuts help Teva raise profits, despite flat sales

Earnings attributed largely to firm’s generics business

Teva Pharma logo

Teva scales back R&D as Copaxone competition looms

Copaxone accounts for almost 40% of its revenue

- PMLiVE

Questions raised about affordability of asthma antibodies

Positive data on GSK and Teva anti-IL-5 candidates at ERS congress highlights cost concerns

- PMLiVE

Teva supports launch of MS help website

Pow Health aims to help patients in Ireland with long term illnesses

- PMLiVE

Teva stakes its claim to the asthma antibody market

Plans to file reslizumab early next year

- PMLiVE

EU hits Servier and generic firms with €428m ‘pay-for-delay’ fine

Follows deals to delay competition for blood pressure drug Coversyl/Aceon

- PMLiVE

Teva’s chair Philip Frost to step down

He will leave the Israeli pharma company by the end of the year

- PMLiVE

Teva restructures to stengthen unit identities

First major change at Israeli firm since Erez Vigodman’s appointment as CEO

- PMLiVE

Teva to use cloud-based CRM for sales force

Picks Veeva’s system to streamline operations

- PMLiVE

Teva backs laquinimod for MS despite CHMP rejection

EMA confirms negative opinion after re-examination

- PMLiVE

Teva launches first generic of GSK’s Lovaza in US

Will have six months of marketing exclusivity for copy of cardiovascular drug

- PMLiVE

Teva backs UK’s dementia drive with $21m investment

Pharma company will support National Institute for Health Research

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links